Search by Drug Name or NDC
NDC 67877-0731-01 Chlordiazepoxide Hydrochloride and Clidinium Bromide 5; 2.5 mg/1; mg/1 Details
Chlordiazepoxide Hydrochloride and Clidinium Bromide 5; 2.5 mg/1; mg/1
Chlordiazepoxide Hydrochloride and Clidinium Bromide is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Ascend Laboratories, LLC. The primary component is CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE.
MedlinePlus Drug Summary
The combination of chlordiazepoxide and clidinium is used along with other medications to treat peptic ulcers, irritable bowel syndrome (IBS; a condition that causes stomach pain, bloating, constipation, and diarrhea), and enterocolitis (swelling in the intestines). Chlordiazepoxide is in a class of medications called benzodiazepines. It works by decreasing abnormal electrical activity in the brain. Clidinium is in a class of medications called anticholinergics. It helps to decrease stomach spasms and cramps.
Related Packages: 67877-0731-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Chlordiazepoxide and Clidinium
Product Information
| NDC | 67877-0731 |
|---|---|
| Product ID | 67877-731_86f797ac-3e72-46c0-a783-2ee15f37100f |
| Associated GPIs | 49109902450110 |
| GCN Sequence Number | 004902 |
| GCN Sequence Number Description | chlordiazepoxide/clidinium Br CAPSULE 5 MG-2.5MG ORAL |
| HIC3 | J2B |
| HIC3 Description | ANTICHOLINERGICS,QUATERNARY AMMONIUM |
| GCN | 74801 |
| HICL Sequence Number | 002037 |
| HICL Sequence Number Description | CHLORDIAZEPOXIDE/CLIDINIUM BROMIDE |
| Brand/Generic | Generic |
| Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 5; 2.5 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
| Labeler Name | Ascend Laboratories, LLC |
| Pharmaceutical Class | Anticholinergic [EPC], Benzodiazepine [EPC], Benzodiazepines [CS], Cholinergic Antagonists [MoA], Decreased Parasympathetic Acetylcholine Activity [PE], Digestive/GI System Activity Alteration [PE], GI Motility Alteration [PE] |
| DEA Schedule | CIV |
| Marketing Category | ANDA |
| Application Number | ANDA214065 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 67877-0731-01 (67877073101)
| NDC Package Code | 67877-731-01 |
|---|---|
| Billing NDC | 67877073101 |
| Package | 100 CAPSULE in 1 BOTTLE (67877-731-01) |
| Marketing Start Date | 2021-04-27 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.37339 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | CHLORDIAZEPOXIDE-CLIDINIUM CAP |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |